IDYA
Price
$25.66
Change
-$0.26 (-1.00%)
Updated
Sep 24, 04:59 PM (EDT)
Capitalization
2.27B
48 days until earnings call
SMMT
Price
$20.51
Change
+$1.36 (+7.10%)
Updated
Sep 24, 04:59 PM (EDT)
Capitalization
14.23B
42 days until earnings call
Interact to see
Advertisement

IDYA vs SMMT

Header iconIDYA vs SMMT Comparison
Open Charts IDYA vs SMMTBanner chart's image
IDEAYA Biosciences
Price$25.66
Change-$0.26 (-1.00%)
Volume$20.3K
Capitalization2.27B
Summit Therapeutics
Price$20.51
Change+$1.36 (+7.10%)
Volume$122.87K
Capitalization14.23B
IDYA vs SMMT Comparison Chart in %
Loading...
IDYA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SMMT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
IDYA vs. SMMT commentary
Sep 25, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is IDYA is a Buy and SMMT is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Sep 25, 2025
Stock price -- (IDYA: $25.93 vs. SMMT: $19.15)
Brand notoriety: IDYA and SMMT are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: IDYA: 82% vs. SMMT: 81%
Market capitalization -- IDYA: $2.27B vs. SMMT: $14.23B
IDYA [@Biotechnology] is valued at $2.27B. SMMT’s [@Biotechnology] market capitalization is $14.23B. The market cap for tickers in the [@Biotechnology] industry ranges from $97.36B to $0. The average market capitalization across the [@Biotechnology] industry is $1.91B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

IDYA’s FA Score shows that 0 FA rating(s) are green whileSMMT’s FA Score has 1 green FA rating(s).

  • IDYA’s FA Score: 0 green, 5 red.
  • SMMT’s FA Score: 1 green, 4 red.
According to our system of comparison, both IDYA and SMMT are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

IDYA’s TA Score shows that 6 TA indicator(s) are bullish while SMMT’s TA Score has 5 bullish TA indicator(s).

  • IDYA’s TA Score: 6 bullish, 3 bearish.
  • SMMT’s TA Score: 5 bullish, 4 bearish.
According to our system of comparison, IDYA is a better buy in the short-term than SMMT.

Price Growth

IDYA (@Biotechnology) experienced а +4.89% price change this week, while SMMT (@Biotechnology) price change was +5.68% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +4.90%. For the same industry, the average monthly price growth was +10.70%, and the average quarterly price growth was +54.52%.

Reported Earning Dates

IDYA is expected to report earnings on Nov 11, 2025.

SMMT is expected to report earnings on Nov 05, 2025.

Industries' Descriptions

@Biotechnology (+4.90% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
SMMT($14.2B) has a higher market cap than IDYA($2.27B). SMMT YTD gains are higher at: 7.313 vs. IDYA (0.895). IDYA has higher annual earnings (EBITDA): -380.2M vs. SMMT (-743.48M). IDYA has more cash in the bank: 670M vs. SMMT (298M). SMMT has less debt than IDYA: SMMT (5.55M) vs IDYA (26.6M). IDYA has higher revenues than SMMT: IDYA (7M) vs SMMT (0).
IDYASMMTIDYA / SMMT
Capitalization2.27B14.2B16%
EBITDA-380.2M-743.48M51%
Gain YTD0.8957.31312%
P/E RatioN/A26.41-
Revenue7M0-
Total Cash670M298M225%
Total Debt26.6M5.55M479%
FUNDAMENTALS RATINGS
IDYA vs SMMT: Fundamental Ratings
IDYA
SMMT
OUTLOOK RATING
1..100
796
VALUATION
overvalued / fair valued / undervalued
1..100
61
Fair valued
95
Overvalued
PROFIT vs RISK RATING
1..100
6952
SMR RATING
1..100
97100
PRICE GROWTH RATING
1..100
4787
P/E GROWTH RATING
1..100
1008
SEASONALITY SCORE
1..100
5050

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

IDYA's Valuation (61) in the null industry is somewhat better than the same rating for SMMT (95) in the Biotechnology industry. This means that IDYA’s stock grew somewhat faster than SMMT’s over the last 12 months.

SMMT's Profit vs Risk Rating (52) in the Biotechnology industry is in the same range as IDYA (69) in the null industry. This means that SMMT’s stock grew similarly to IDYA’s over the last 12 months.

IDYA's SMR Rating (97) in the null industry is in the same range as SMMT (100) in the Biotechnology industry. This means that IDYA’s stock grew similarly to SMMT’s over the last 12 months.

IDYA's Price Growth Rating (47) in the null industry is somewhat better than the same rating for SMMT (87) in the Biotechnology industry. This means that IDYA’s stock grew somewhat faster than SMMT’s over the last 12 months.

SMMT's P/E Growth Rating (8) in the Biotechnology industry is significantly better than the same rating for IDYA (100) in the null industry. This means that SMMT’s stock grew significantly faster than IDYA’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
IDYASMMT
RSI
ODDS (%)
Bearish Trend 2 days ago
72%
Bullish Trend 2 days ago
73%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
81%
Bullish Trend 2 days ago
87%
Momentum
ODDS (%)
Bullish Trend 2 days ago
75%
Bullish Trend 2 days ago
89%
MACD
ODDS (%)
Bullish Trend 2 days ago
82%
N/A
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
77%
Bullish Trend 2 days ago
87%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
81%
Bearish Trend 2 days ago
83%
Advances
ODDS (%)
Bullish Trend 2 days ago
77%
Bullish Trend 2 days ago
86%
Declines
ODDS (%)
Bearish Trend 10 days ago
77%
Bearish Trend 8 days ago
82%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
73%
Bullish Trend 2 days ago
90%
Aroon
ODDS (%)
Bullish Trend 2 days ago
81%
Bearish Trend 2 days ago
88%
View a ticker or compare two or three
Interact to see
Advertisement
IDYA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SMMT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
PSL108.640.03
+0.02%
Invesco DW Consumer Staples Momt ETF
BBAGF42.50N/A
N/A
BB Biotech AG
STEW18.18-0.06
-0.33%
SRH Total Return Fund
CSMD33.59-0.25
-0.74%
Congress SMid Growth ETF
QQQS32.65-0.25
-0.76%
Invesco NASDAQ Future Gen 200 ETF

IDYA and

Correlation & Price change

A.I.dvisor indicates that over the last year, IDYA has been loosely correlated with IMNM. These tickers have moved in lockstep 60% of the time. This A.I.-generated data suggests there is some statistical probability that if IDYA jumps, then IMNM could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To IDYA
1D Price
Change %
IDYA100%
+0.04%
IMNM - IDYA
60%
Loosely correlated
+8.09%
SYRE - IDYA
59%
Loosely correlated
+4.77%
NRIX - IDYA
58%
Loosely correlated
-2.25%
CGON - IDYA
57%
Loosely correlated
-0.92%
CRNX - IDYA
57%
Loosely correlated
+6.35%
More

SMMT and

Correlation & Price change

A.I.dvisor indicates that over the last year, SMMT has been closely correlated with BCDA. These tickers have moved in lockstep 69% of the time. This A.I.-generated data suggests there is a high statistical probability that if SMMT jumps, then BCDA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To SMMT
1D Price
Change %
SMMT100%
+0.26%
BCDA - SMMT
69%
Closely correlated
+27.03%
BNTX - SMMT
49%
Loosely correlated
-0.46%
TIL - SMMT
49%
Loosely correlated
-8.83%
IMNM - SMMT
43%
Loosely correlated
+8.09%
IDYA - SMMT
42%
Loosely correlated
+0.04%
More